FDA Approves First Branded Ocular Anesthetic In Almost 14 Years
The FDA approved Harrow Health Inc (NASDAQ:HROW) and Sintetica S.A’s Iheezo (chloroprocaine hydrochloride ophthalmic gel) 3% for ocular surface anesthesia. Iheezo is a…
Ryder System, Harrow Health And Other Big Gainers From Tuesday
U.S. stocks closed mixed with the Dow Jones dropping around 125 points on Tuesday. Here is the list of some big stocks recording gains in the previous session.
Harrow Announces U.S. FDA Approval of IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia
IHEEZO™ Represents the First Approved Use in the U.S. Ophthalmic Market of Chloroprocaine Hydrochloride and the First Branded Ocular Anesthetic Approved for the U.S. Ophthalmic Market in Nearly 14
B. Riley Securities Reinstates Buy on Harrow Health, Announces $17 Price Target
B. Riley Securities analyst Sahil Kazmi reinstates Harrow Health (NASDAQ:HROW) with a Buy and announces $17 price target.
Harrow Health Q2 EPS $0.01 Beats $(0.01) Estimate, Sales $23.30M Beat $22.07M Estimate
Harrow Health (NASDAQ:HROW) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.01) by 200 percent. This is a 109.09 percent increase over losses of $(0.11) per share from the
Earnings Scheduled For August 9, 2022
Companies Reporting Before The Bell
• Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second quarter.
B. Riley Securities Maintains Buy on Harrow Health, Raises Price Target to $20
B. Riley Securities analyst Justin Walsh maintains Harrow Health (NASDAQ:HROW) with a Buy and raises the price target from $17 to $20.
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 807 companies reached new 52-week lows.